Merck to Acquire Cubist Pharmaceuticals: What It Means for Mutual Fund Investors (MRK, CBST)

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.
Not interested

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed Income Channel

Fixed income news, reports, video and more.

Municipal Bonds Channel

Municipal bonds news, reports, video and more.

Practice Management Channel

Practice management news, reports, video and more.

Portfolio Management Channel

Portfolio management news, reports, video and more.

Retirement Channel

Retirement news, reports, video and more.

Strategists Channel

Learn from industry thought leaders and expert market participants.

Calvert’s Advisor Resource Center

Deepen your understanding of Responsible Investing and learn how it can potentially help you build a more successful practice.

Screener
Funds
Categories

18 Most Popular Mutual Fund Categories

Canada Equity Funds Global Equity Funds Micro-Cap Equity Funds Precious Metals Equity Funds Water Equity Funds
Consumer Staples Funds US Funds China Funds Israel Funds Retirement Income Funds
Bear Market Strategy Funds Market Neutral Funds Alternative Funds Commodity Funds
Currency Funds Mortgage-Backed Securities Funds High Yield Municipal Bond Funds Money Market Funds

View All Categories

Fund Companies

15 Most Popular Fund Companies

Vanguard Fidelity Investments American Funds T. Rowe Price
JPMorgan BlackRock Dimensional Fund Advisors Franklin Templeton
PIMCO Goldman Sachs Federated MFS
Charles Schwab John Hancock Invesco

View All Fund Companies

15 Most Popular Fund Company Quick Screens

Vanguard Index Funds Vanguard Retirement Funds Vanguard Money Market Funds Fidelity Index Funds
Fidelity Money Market Funds Fidelity Blue Chip Growth Equity Funds American Balanced Funds T. Rowe Price Blue Chip Growth Equity Funds
Blackrock Global Allocation Funds Franklin Income Funds PIMCO Income Funds Charles Schwab Index Funds
Charles Schwab Money Market Funds Invesco Real Estate Funds Matthews Asia International Funds

View All Fund Company Quick Screens

Articles

Articles

Mutual Fund Education Index Fund Center Domestic Stock Funds International and Global Stock Funds Target-Date Funds
Fixed-Income Funds Asset Allocation Specialized Funds Enhanced Index Funds Actively Managed Funds
No-Load Funds Bond Funds Equity Funds Hybrid Funds Resources For Mutual Fund Investors
Q&As and Interviews Lighter Side: Quizzes and More Taxation Expert Analysis and Commentary News
Advisors

Advisor Access

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Practice Management

Content focused on helping financial advisors build successful client relationships and grow their business.

Portfolio Management

Content geared towards helping financial advisors build better client portfolios.

Expert Opinion

Get insights on the industry trends and investment news from leading fund managers and experts.

Advisor Access
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Merck to Acquire Cubist Pharmaceuticals: What It Means for Mutual Fund Investors (MRK, CBST)

Shauna O'Brien

|

Merck & Company logo
Merck (MRK) announced on Monday morning that it has agreed to purchase Cubist Pharmaceuticals (CBST). Here’s what the news means for mutual funds investors.

Inside the Deal

Merck announced that it will purchase the antibiotics maker for $8.4 billion in cash. The news sent shares of Cubist Pharmaceuticals soaring over 35% on Monday morning.

Cubist focuses on drugs that treat infectious diseases, usually in a hospital setting. According to Cubist, it plans to release four new drugs by 2020. This purchase will allow MRK to continue its strategy to focus on areas including diabetes, acute hospital care, vaccines and oncology.

Mutual Funds to Watch

The funds listed below currently hold the largest stake in Cubist Pharmaceuticals. These funds may be a good alternative to buying the individual stock.
Symbol Mutual Fund Stake
PVSAX Putnam Capital Spectrum 6.16%
PYSAX Putnam Equity Spectrum 2.83%
VGHCX Vanguard Health Care 2.60%
The funds below currently have the largest stakes in Merck:
Symbol Mutual Fund Stake
VTSMX Vanguard Total Stock Market Index 1.68%
VGHCX Vanguard Health Care 1.17%
VFINX Vanguard 500 Index 1.07%

The Bottom Line

The funds above allow investors to gain exposure to Merck and Cubist, as well as many other holdings and industries. Investors investing in health care focused mutual funds may also consider Fidelity Select Health Care Portfolio (FSPHX) and T. Rowe Price Health Sciences Fund (PRHSX).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Read Next

Merck & Company logo

Merck to Acquire Cubist Pharmaceuticals: What It Means for Mutual Fund Investors (MRK, CBST)

Shauna O'Brien

|

Merck (MRK) announced on Monday morning that it has agreed to purchase Cubist Pharmaceuticals (CBST). Here’s what the news means for mutual funds investors.

Inside the Deal

Merck announced that it will purchase the antibiotics maker for $8.4 billion in cash. The news sent shares of Cubist Pharmaceuticals soaring over 35% on Monday morning.

Cubist focuses on drugs that treat infectious diseases, usually in a hospital setting. According to Cubist, it plans to release four new drugs by 2020. This purchase will allow MRK to continue its strategy to focus on areas including diabetes, acute hospital care, vaccines and oncology.

Mutual Funds to Watch

The funds listed below currently hold the largest stake in Cubist Pharmaceuticals. These funds may be a good alternative to buying the individual stock.
Symbol Mutual Fund Stake
PVSAX Putnam Capital Spectrum 6.16%
PYSAX Putnam Equity Spectrum 2.83%
VGHCX Vanguard Health Care 2.60%
The funds below currently have the largest stakes in Merck:
Symbol Mutual Fund Stake
VTSMX Vanguard Total Stock Market Index 1.68%
VGHCX Vanguard Health Care 1.17%
VFINX Vanguard 500 Index 1.07%

The Bottom Line

The funds above allow investors to gain exposure to Merck and Cubist, as well as many other holdings and industries. Investors investing in health care focused mutual funds may also consider Fidelity Select Health Care Portfolio (FSPHX) and T. Rowe Price Health Sciences Fund (PRHSX).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Read Next

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.

X